VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases.

Learn more

VALEDIA®

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®.

Read the press release

Prediabetes

VALBIOTIS publishes the first prediabetes market data.

Read the press release

VALEDIA®

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group.

Read the press release
S c r o l l

Products

.01

Pipeline

4 products in clinical development

Learn more

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Positive Phase IIA clinical study

Learn more

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

Learn more

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

Learn more

.05

TOTUM-63 – Non-alcoholic hepatic steatosis

Non-alcoholic hepatic steatosis
• Reduction of steatosis, risk factor for NASH
• Clinical Phase I/II positive

Learn more

.06

TOTUM-63 – Arterial hypertension

Arterial hypertension
- Reduces hypertension, a risk factor for cardiovascular diseases
- Positive Phase IIA clinical study

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

28.01.2020

Biomed Event

En savoir plus
16.10.2019

French Society of Financial Analysts (SFAF)

En savoir plus
14.10.2019

European Large & Midcap Event

En savoir plus
16.09.2019

Annual Meeting of the European Association for the Study of Diabetes (EASD)

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Follow us!

See more